CN116855470A - 酰基转移酶MsAcT变体、融合蛋白及其固定方法和应用 - Google Patents
酰基转移酶MsAcT变体、融合蛋白及其固定方法和应用 Download PDFInfo
- Publication number
- CN116855470A CN116855470A CN202311008578.7A CN202311008578A CN116855470A CN 116855470 A CN116855470 A CN 116855470A CN 202311008578 A CN202311008578 A CN 202311008578A CN 116855470 A CN116855470 A CN 116855470A
- Authority
- CN
- China
- Prior art keywords
- msact
- variant
- acyltransferase
- fusion protein
- acylase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000057234 Acyl transferases Human genes 0.000 title claims abstract description 40
- 108700016155 Acyl transferases Proteins 0.000 title claims abstract description 40
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 24
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 12
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 34
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 34
- 229920005989 resin Polymers 0.000 claims abstract description 20
- 239000011347 resin Substances 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 230000021736 acetylation Effects 0.000 claims abstract description 10
- 238000006640 acetylation reaction Methods 0.000 claims abstract description 10
- 230000026792 palmitoylation Effects 0.000 claims abstract description 9
- 239000013613 expression plasmid Substances 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- 102220328583 rs111822347 Human genes 0.000 claims abstract description 5
- 230000035772 mutation Effects 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 7
- 239000003822 epoxy resin Substances 0.000 claims description 5
- 229920000647 polyepoxide Polymers 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 125000003700 epoxy group Chemical group 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 230000003197 catalytic effect Effects 0.000 abstract description 6
- 239000006227 byproduct Substances 0.000 abstract description 5
- 102200101935 rs72554344 Human genes 0.000 abstract description 3
- 238000000746 purification Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000010933 acylation Effects 0.000 description 7
- 238000005917 acylation reaction Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 241000187480 Mycobacterium smegmatis Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ISJKIHHTPAQLLW-TUFLPTIASA-N (2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ISJKIHHTPAQLLW-TUFLPTIASA-N 0.000 description 1
- QTEWJFPLRGWOOU-IHRRRGAJSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 QTEWJFPLRGWOOU-IHRRRGAJSA-N 0.000 description 1
- LDWBQGACJJOIKA-RHEFHGCGSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O LDWBQGACJJOIKA-RHEFHGCGSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明公开了一种酰基转移酶MsAcT变体，是在野生型酰基转移酶MsAcT的基础上进行S11C、T93A、F150I、F154A、T161S五位点突变。还公开了其融合蛋白、编码基因、表达质粒及宿主菌，以及其固定方法和在催化寡肽乙酰基化或棕榈酰基化中的应用。本发明对野生型酰基转移酶MsAcT改造，获得五位点突变体，并且在突变体的N端***促溶的Spy‑GST标签，获得的酰基转移酶变体可以生物合成，且酶活明显高于野生型酰基转移酶。本发明还将酰基转移酶变体固定在SpyCather树脂上，获得稳定性更高的固定化酰基转移酶变体，使其更具有工业应用的价值。本发明的固定化酰基转移酶变体可催化寡肽乙酰基化和棕榈酰基化，催化效率高，且不产生有害副产物。
Description
技术领域
本发明涉及一种酰基转移酶MsAcT变体、融合蛋白、编码基因、表达质粒及宿主菌，以及其固定方法和在催化寡肽乙酰基化或棕榈酰基化中的应用，涉及生物合成技术领域。
背景技术
寡肽又称为小肽、低聚肽或称为小分子活性肽，是由2～10个氨基酸彼此缩合形成的化合物，是多肽的一种分类。20世纪60年代Newey和Smyth(1959,1960)第一次提供了肽被完整吸收的资料。蛋白质在小肠中被消化成氨基酸与寡肽，且寡肽可以完整的进入肠粘膜细胞并水解成氨基酸进入血液循环。寡肽具有不需要消化直接吸收、吸收时不消耗能量、不增加肠胃功能负担、100％被人体吸收等特点。寡肽的修饰主要为酰基化修饰，包括乙酰化和棕榈酰化，修饰后的寡肽往往具有活性好、透皮性高和稳定性好等优点，因此在合成寡肽时，往往会引入酰基化修饰来提高寡肽产品的性能。
传统的寡肽合成主要分为化学合成和生物合成。化学合成利用固相或者液相介质，将肽链依照顺序逐个添加到合成中间产物上。这种化学合成的方法适用于二肽或者三肽的合成，但应用在较长寡肽的合成时，会出现反应步骤多，副产物和中间产物多，产量低和提纯困难等问题。生物合成是利用生物***的蛋白表达技术，将寡肽融合蛋白表达在宿主内部，再经过蛋白纯化和寡肽释放来获得目的寡肽。这种方法的优势是不受寡肽长度和氨基酸序列的影响，可以简单高效地合成寡肽，副产物少，也是目前工业上合成寡肽的重要方法。但是，生物合成的寡肽往往不带有酰基化修饰，因此需在寡肽合成制备后，再进行化学酰基化修饰，这种修饰方法对寡肽的性能和稳定都是极大的挑战，并容易产生非理想的有害副产物。因此，更加绿色高效的酶介导寡肽酰基化修饰方法，也是寡肽生物合成领域的迫切需求。
耻垢分枝杆菌(Mycobacterium smegmatis)的酰基转移酶MsAcT(NCBI SequenceID:WP_011731199.1)是近年来发现的高效酰基转移酶，具有效率高、底物谱广泛、催化条件温和和催化环境适应度高等优点，已经广泛应用在合成生物学领域各类药物中间体和化妆品原料的合成催化过程，是酶催化合成领域的明星蛋白。因此，MsAcT具有催化寡肽酰基化修饰的潜能。
发明内容
本发明公开了一种酰基转移酶MsAcT变体，是在野生型酰基转移酶MsAcT的基础上进行S11C、T93A、F150I、F154A、T161S五位点突变。
为提高其溶解性，在酰基转移酶MsAcT变体的N端加入Spy-GST标签，带有标签的酰基转移酶MsAcT变体融合蛋白的氨基酸序列如SEQ ID NO:1所示，编码基因序列如SEQ IDNO:2所示。
本发明还公开了上述酰基转移酶MsAcT变体融合蛋白的表达质粒，质粒载体为pET22b，酰基转移酶MsAcT变体融合蛋白的编码基因***到pET22b的PelB信号肽下游。将表达质粒转入到Rosetta(DE3)感受态中，获得表达酰基转移酶MsAcT变体融合蛋白的宿主菌。
为提高酰基转移酶MsAcT变体融合蛋白的稳定性，本发明还公开了上述的酰基转移酶MsAcT变体融合蛋白的固定方法，其步骤包括：
(1)将SpyCather-Cys加入到环氧基树脂中，制得SpyCather树脂；
(2)将上述的宿主菌培养以表达酰基转移酶MsAcT变体融合蛋白，破碎菌体，离心获取上清液，上清液与SpyCather树脂一起孵育，离心，获得固定有酰基转移酶MsAcT变体的SpyCather树脂。
优选的，所述环氧基树脂为是表面含有环氧基团，能与伯胺或者巯基进行共价交联反应的树脂；所述SpyCather-Cys是指含有半胱氨酸残基的SpyCather蛋白。SpyCather-Cys的半胱氨酸残基与环氧基团反应，使得SpyCather蛋白耦合到树脂表面。
本发明对野生型酰基转移酶MsAcT改造，获得S11C、T93A、F150I、F154A、T161S五位点突变体，并且在突变体的N端***促溶的Spy-GST标签，获得的酰基转移酶变体可以生物合成，且酶活明显高于野生型酰基转移酶。本发明还将酰基转移酶变体固定在SpyCather树脂上，获得稳定性更高的固定化酰基转移酶变体，使其更具有工业应用的价值。本发明的固定化酰基转移酶变体可催化寡肽乙酰基化和棕榈酰基化，催化效率高，且产物纯净，不产生有害副产物。
附图说明
图1为野生型MsAcT表达和纯化结果。
图2为重组MsAcT野生型表达和纯化结果。
图3为重组MsAcT变体表达和纯化结果。
图4为野生型MsAcT与MsAcT变体酶活性比较结果。
图5为MsAcT变体固定化原理图。
图6为MsAcT变体在固定化前后酶活比较结果。
图7为MsAcT变体催化寡肽乙酰基化和棕榈酰基化的化学式。
具体实施方式
以下结合附图，通过实施例进一步说明本发明，但不作为对本发明的限制。以下提供了本发明实施方案中所使用的具体材料及其来源。但是，应当理解的是，这些仅仅是示例性的，并不意图限制本发明，与如下试剂和仪器的类型、型号、品质、性质或功能相同或相似的材料均可以用于实施本发明。下述实施例中所使用的实验方法如无特别说明，均为常规方法。下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
实施例1
在本实施例中，我们对耻垢分枝杆菌(Mycobacterium smegmatis)的酰基转移酶MsAcT(NCBI Sequence ID:WP_011731199.1)进行酶活和序列同源性改造，使用的DrugDiscovery和Consensus Finder，最终获得S11C、T93A、F150I、F154A、T161S五位点突变体。
我们将获得的野生型和突变体进行了密码子优化，表达在pET28a载体上，发现表达的蛋白为无活性的包涵体(如图1)。为了进一步提高蛋白表达的可溶性，我们在突变体前面***了促溶的Spy-GST标签，最终获得的酶变体序列见SEQ ID NO:1，核苷酸序列经密码子优化后见SEQ ID NO:2。为了进一步提高蛋白的可溶性，我们将合成的SEQ ID NO:2***到pET22b的PelB的信号肽下游，使用的酶切位点为NcoI和XhoI双酶切，让表达的融合蛋白通过PelB信号肽分泌到大肠杆菌的周质空间中。野生型的MsAcT做同样的处理。
构建好的质粒转入到全式金生物的Rosetta(DE3)大肠杆菌感受态中，冰浴30min后，42℃热激90s，继续冰浴5min后，涂布到含100mg/L氨苄霉素的LB固体平板上。37℃倒置培养过夜。挑取单克隆于含100mg/L氨苄霉素的LB液体培养基中，200rpm 37℃震荡培养至OD600值达到0.6，加入0.2mM IPTG，25℃200rpm继续培养24h。离心收集菌株，加入10mM PBS(含蛋白酶抑制剂)重悬进行高压破碎后，使用天地人和的HisPur Ni NTA kit和GSTPurGlutathione kit按照其说明书进行蛋白纯化。纯化结果见图1、图2和图3，其中图1为野生型MsAcT的表达纯化结果，图2为融合了Spy-GST标签的野生型MsAcT的表达纯化结果，图3为融合了Spy-GST标签的MsAcT变体的表达纯化结果，融合了Spy-GST标签的MsAcT变体蛋白可溶性表达更好，纯化效果更好。我们随后对MsAcT进行了酰基转移酶活性测试，使用原鑫生物的酰基转移酶(AAT)活性检测试剂盒，酶活结果见图4，将野生型MsAcT的酶活定义为1，可以看出，MsAcT变体的酰基转移酶活性是野生型的2.8倍。
实施例2
在本实施例中，我们对表达的酰基转移酶变体进行了固定化，原理见图5。
双酚A型缩水甘油醚环氧树脂(Sigma Aldrich)经聚合固化后，使用研磨破碎机制成2-3um的树脂颗粒。取1g树脂颗粒，加入10mg SpyCather-Cys(Bio-rad,TZC025)后，在0.5M氯化钠(pH 7.4)的条件下，20℃处理6h。离心获得树脂沉淀，即为制备好的SpyCather树脂。
挑取单克隆于含100mg/L氨苄霉素的LB液体培养基中，200rpm 37℃震荡培养至OD600值达到0.6时，加入0.2mM IPTG，25℃200rpm继续培养24h。离心收集菌株，加入10mMPBS(含蛋白酶抑制剂)重悬进行高压破碎后，取上清，加入质量比0.2％的制备好的树脂，室温震荡孵育2h后，离心收集树脂，PBS清洗树脂3次后备用。使用原鑫生物的酰基转移酶(AAT)活性检测试剂盒检测固定化前后的酰基转移酶变体的活性和稳定性。结果见图6，固定化的酰基转移酶变体仍保留80％的酰基转移酶变体活性，且具有更好的稳定性。
实施例3
在本实施例中，我们利用固定化的酰基转移酶变体对小分子寡肽进行催化测试。
乙酰基化催化(原理图见图7)：10ml体系中加入1ml乙酸乙酯，0.5g的酰基转移酶固定化树脂，0.5g寡肽,100mM磷酸盐缓冲液，pH 8.0。25℃搅拌过夜。HPLC检测乙酰化效率。结果显示，各寡肽乙酰基化比例为二肽-1(71.4％)、四肽-5(52.6％)、四肽-9(57.2％)、六肽-8(35.3％)。
棕榈酰基化催化(原理图见图7)：10ml体系中加入100ul棕榈酸乙酯，500ul叔丁醇，0.5g的酰基转移酶固定化树脂，0.5g寡肽,100mM磷酸盐缓冲液，pH 8.0。25℃搅拌过夜。HPLC检测棕榈酰化效率。结果显示，各寡肽棕榈酰基化比例为三肽-1(17.8％)、三肽-5(12.1％)、三肽-8(9.5％)、四肽-7(13.9％)、四肽-11(8.4％)、五肽-4(12.5％)。
Claims (10)
1.一种酰基转移酶MsAcT变体，其特征在于在野生型酰基转移酶MsAcT的基础上进行S11C、T93A、F150I、F154A、T161S五位点突变。
2.一种酰基转移酶MsAcT变体融合蛋白，其特征在于在权利要求1所述的酰基转移酶MsAcT变体N端加入Spy-GST标签，其氨基酸序列如SEQ ID NO:1所示。
3.权利要求2所述的酰基转移酶MsAcT变体融合蛋白的编码基因。
4.根据权利要求3所述的酰基转移酶MsAcT变体融合蛋白的编码基因，其特征在于其DNA序列如SEQ ID NO:2所示。
5.权利要求2所述的酰基转移酶MsAcT变体融合蛋白的表达质粒。
6.根据权利要求5所述的酰基转移酶MsAcT变体融合蛋白的表达质粒，其特征在于质粒载体为pET22b，酰基转移酶MsAcT变体融合蛋白的编码基因***到pET22b的PelB信号肽下游。
7.包含权利要求5或6所述的酰基转移酶MsAcT变体融合蛋白的表达质粒的宿主菌。
8.权利要求1所述的酰基转移酶MsAcT变体或权利要求2所述的酰基转移酶MsAcT变体融合蛋白在催化寡肽乙酰基化或棕榈酰基化中的应用。
9.权利要求2所述的酰基转移酶MsAcT变体融合蛋白的固定方法，其特征在于其步骤包括：
(1)将SpyCather-Cys加入到环氧基树脂中，制得SpyCather树脂；
(2)将权利要求7所述的宿主菌培养以表达酰基转移酶MsAcT变体融合蛋白，破碎菌体，离心获取上清液，上清液与SpyCather树脂一起孵育，离心，获得固定有酰基转移酶MsAcT变体的SpyCather树脂。
10.根据权利要求9所述的固定方法，其特征在于所述环氧基树脂为是表面含有环氧基团，能与伯胺或者巯基进行共价交联反应的树脂；所述SpyCather-Cys是指含有半胱氨酸残基的SpyCather蛋白。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310835442 | 2023-07-10 | ||
| CN2023108354427 | 2023-07-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116855470A true CN116855470A (zh) | 2023-10-10 |
| CN116855470B CN116855470B (zh) | 2024-06-11 |
Family
ID=
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008019069A2 (en) * | 2006-08-03 | 2008-02-14 | Danisco Us, Inc., Genencor Division | Enzymatic aqueous acylation |
| US20080145353A1 (en) * | 2003-12-03 | 2008-06-19 | Amin Neelam S | Perhydrolase |
| WO2009002480A2 (en) * | 2007-06-26 | 2008-12-31 | Danisco Us, Inc., Genencor Division | Acyl transferase having altered substrate specificity |
| CN101535481A (zh) * | 2006-11-09 | 2009-09-16 | 丹尼斯科美国公司 | 用于生产长链过酸的酶 |
| CN102016050A (zh) * | 2005-12-09 | 2011-04-13 | 金克克国际有限公司 | 用于去污的酰基转移酶 |
| WO2013134139A1 (en) * | 2012-03-09 | 2013-09-12 | Matrix Genetics, Llc | Modified diacylglycerol acyltransferase proteins and methods of use thereof |
| CN115806952A (zh) * | 2022-09-14 | 2023-03-17 | 福建师范大学 | 可与葡萄糖氧化酶高效偶联的耻垢分枝杆菌酰基转移酶突变体及其制备方法和应用 |
| WO2023118363A1 (en) * | 2021-12-22 | 2023-06-29 | BRAIN Biotech AG | Method for the synthesis of a carbonyl-functionalised adduct |
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080145353A1 (en) * | 2003-12-03 | 2008-06-19 | Amin Neelam S | Perhydrolase |
| CN102016050A (zh) * | 2005-12-09 | 2011-04-13 | 金克克国际有限公司 | 用于去污的酰基转移酶 |
| WO2008019069A2 (en) * | 2006-08-03 | 2008-02-14 | Danisco Us, Inc., Genencor Division | Enzymatic aqueous acylation |
| CN101535481A (zh) * | 2006-11-09 | 2009-09-16 | 丹尼斯科美国公司 | 用于生产长链过酸的酶 |
| WO2009002480A2 (en) * | 2007-06-26 | 2008-12-31 | Danisco Us, Inc., Genencor Division | Acyl transferase having altered substrate specificity |
| WO2013134139A1 (en) * | 2012-03-09 | 2013-09-12 | Matrix Genetics, Llc | Modified diacylglycerol acyltransferase proteins and methods of use thereof |
| WO2023118363A1 (en) * | 2021-12-22 | 2023-06-29 | BRAIN Biotech AG | Method for the synthesis of a carbonyl-functionalised adduct |
| CN115806952A (zh) * | 2022-09-14 | 2023-03-17 | 福建师范大学 | 可与葡萄糖氧化酶高效偶联的耻垢分枝杆菌酰基转移酶突变体及其制备方法和应用 |
Non-Patent Citations (5)
| Title |
|---|
| CONTENTE, M.L 等: "A strategic Ser/Cys exchange in the catalytic triad unlocks an acyltransferase-mediated synthesis of thioesters and tertiary amides", 《NAT CATAL 》, vol. 3, pages 1020 * |
| FINNVEDEN 等: "Mono-substitution of symmetric diesters: selectivity of Mycobacterium smegmatis acyltransferase variants", 《FINNVEDEN》, vol. 9, no. 18, pages 4920 - 4927 * |
| GODEHARD等: "Protein Engineering for Enhanced Acyltransferase Activity, Substrate Scope, and Selectivity of the Mycobacterium smegmatis Acyltransferase MsAcT", 《ACS CATALYSIS》, vol. 10, no. 14, pages 5 - 6 * |
| 杨志刚 等: "Canavan病一例临床和天冬氨酸酰基转移酶基因突变分析", 《中华神经科杂志》, vol. 52, no. 6, pages 493 - 497 * |
| 牛晶红: "Mycobacterium smegmatis酰基转移酶的表面修饰及其突变体的酶学常数分析", 《中国优秀硕士学位论文全文数据库基础科学辑》, no. 12, pages 006 - 101 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wan et al. | Pyrrolysyl-tRNA synthetase: an ordinary enzyme but an outstanding genetic code expansion tool | |
| Altenbuchner et al. | Hydantoinases and related enzymes as biocatalysts for the synthesis of unnatural chiral amino acids | |
| Kumar et al. | Microbial proteases in peptide synthesis: approaches and applications | |
| CA2634269A1 (en) | Novel peptide-forming enzyme gene | |
| CN106367377B (zh) | 一种蔗糖异构酶的固定化方法 | |
| WO2022001121A1 (zh) | 一种用于合成戊二胺的赖氨酸脱羧酶及其应用 | |
| CN101165190A (zh) | 固定化双酶法制备n-乙酰神经氨酸 | |
| Bauer et al. | Synthesis of a linear gramicidin by a combination of biosynthetic and organic methods | |
| CN116855470B (zh) | 酰基转移酶MsAcT变体、融合蛋白及其固定方法和应用 | |
| CN116855470A (zh) | 酰基转移酶MsAcT变体、融合蛋白及其固定方法和应用 | |
| CN109609536B (zh) | 一种全细胞一步合成l-肌肽的方法 | |
| CN114606221B (zh) | 固定化酶、其制备方法及应用 | |
| CN114107150B (zh) | 一种α-氨基酸酯酰基转移酶在细胞表面表达的重组大肠杆菌与应用 | |
| CN107099523B (zh) | 头孢拉定合成酶突变体及其编码基因 | |
| CN112481320B (zh) | 一种催化效率高的制备(-)γ-内酰胺的方法 | |
| US11760988B2 (en) | L-aspartate alpha-decarboxylase mutant and application thereof | |
| CN108949736B (zh) | 一种高选择性头孢拉定合成酶突变体及其编码基因 | |
| CN109913436A (zh) | 含有一个或几个点突变的头孢菌素c酰化酶突变体及其制备方法 | |
| CN110218715B (zh) | 碳酸酐酶XiCA及其编码基因和应用 | |
| Kurochkina et al. | Alpha-amino acid ester hydrolases: properties and applications | |
| EP0975742B1 (en) | Aminopeptidase derived from bacillus licheniformis and process for preparation of natural type proteins | |
| CN117721165B (zh) | Atp再生体系和多肽的合成方法 | |
| CN114934037B (zh) | 用于生产3-氨基丙腈的天冬氨酸酶突变体 | |
| CN115948482B (zh) | 一种2，4-二羟基丁酸生物合成途径的构建方法及应用 | |
| CN108060186A (zh) | 一种对硝基苄醇丙二酸单酯的生物制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |